Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Completed
Merck KGaA
Phase 2
2007-01-01
This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind,
active-comparator, dose-finding study to evaluate a new investigational long-acting follicle
stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive
technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection
[IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently
marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to
the number of fertilized oocytes.
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Completed
Merck KGaA, Darmstadt, Germany
Phase 2
2007-01-01
This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind,
active-comparator, dose-finding study to evaluate a new investigational long-acting follicle
stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive
technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection
[IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently
marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to
the number of fertilized oocytes.
REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Terminated
Stem Cell Therapeutics Corp.
Phase 2
2008-03-01
Primary objective: To assess the neurological outcome in acute ischemic stroke patients
treated with NTx™-265, when compared with patients given a placebo control.
Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute
ischemic stroke patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.